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Abstract
Background: Current guidelines on the management of urinary tract infection recommend
treating febrile urinary tract infection or acute pyelonephritis with antimicrobials for at least 14
days. Few randomized trials showed the effectiveness of treatment durations of 5 to 7 days but this
has only been studied in young previously healthy women.
Methods/Design: A randomized placebo-controlled double-blind multicenter non-inferiority trial
in which 400 patients with community acquired febrile urinary tract infection will be randomly
allocated to a short treatment arm (7 days of ciprofloxacin or 7 days of empirical β-lactams ±
gentamicin intravenously with early switch to oral ciprofloxacin followed by 7 days of blinded
placebo) or standard treatment arm (7 days of ciprofloxacin or 7 days of empirical β-lactams ±
gentamicin intravenously with early switch to oral ciprofloxacin followed by 7 days of blinded
ciprofloxacin). The study is performed in the Leiden region in which one university hospital, 6
general hospitals and 32 primary health care centers are clustered. Patients eligible for
randomization are competent patients aged 18 years or above with a presumptive diagnosis of
acute pyelonephritis as defined by the combination of fever, one or more symptoms of urinary tract
infection and a positive urine nitrate test and/or the presence of leucocyturia. Exclusion criteria are
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BMC Infectious Diseases 2009, 9:131 http://www.biomedcentral.com/1471-2334/9/131known allergy to fluoroquinolones, female patients who are pregnant or lactating, polycystic kidney
disease, permanent renal replacement therapy, kidney transplantation, isolation of ciprofloxacin-
resistant causal uropathogen, renal abscess, underlying chronic bacterial prostatitis, metastatic
infectious foci and inability to obtain follow-up. The primary endpoint is the clinical cure rate
through the 10- to 18-day post-treatment visit. Secondary endpoints are the microbiological cure
rate 10- to 18-day post-treatment, the 30- and 90-day overall mortality rate, the clinical cure rate
70- to 84-day post-treatment, relapse rate of UTI and adverse events or complications during 90
days of follow-up.
Discussion: This study aims to demonstrate that 7 days of antimicrobial treatment is non-inferior
as compared with 14 days of treatment in patients with febrile urinary tract infection. In addition,
it will generate insights into the side-effects of antimicrobial treatment in relation to its duration.
The study population will also include men, the elderly and patients with significant co-morbidity.
Reflecting daily practice of primary health care and emergency departments, the results of this
study can be generalized to other locations.
Trial registration: (Trial registration at clinicaltrials.gov: NCT00809913 and trialregister.nl:
NTR01583)
Background
Fever in urinary tract infection (UTI) suggests the presence
of tissue inflammation and is therefore considered to be a
sign of acute pyelonephritis (AP) [1,2]. In 2000, the esti-
mated direct and indirect costs of acute AP in the United
States were $2.14 billion which is predominantly related
to hospitalization [3]. In the last decades hospitalization
rates of patients with AP has decreased from almost 100%
to 10–30% [4-6]. The outpatient management of patients
with AP has become popular as have oral antimicrobial
treatment regiments and shortening of treatment duration
[7-10]. However, such approaches have only been studied
in the setting of uncomplicated AP, defined as AP in a
young otherwise healthy non-pregnant woman without
co-morbidity. In contrast to this, the optimal treatment of
patients with complicated AP remains unclear and, not
surprisingly, treatment guidelines therefore almost exclu-
sively discuss uncomplicated AP [11,12]. Current strate-
gies recommend antimicrobial treatment for at least 14
days [13-16].
Facing the aging of the general population it is challeng-
ing to better define the optimal treatment for AP in an
unselected population including the elderly, men and
patients with co-morbidity. Moreover, fluoroquinolones,
being the preferred oral empirical treatment for AP, are
associated with considerable side effects such as dysglyc-
emia and Clostridium difficile infections, especially in the
elderly and subjects with co-morbidity [17,18]. Therefore
it is questionable whether the benefit of antimicrobial
treatment of AP at the end of a 14-day antimicrobial treat-
ment still outweighs its potential side effects.
We will conduct a multicenter, randomized, double-
blind, non-inferiority trial to determine whether the effi-
cacy and safety of a 7-day antimicrobial regimen is similar
to a 14-day antimicrobial regimen in unselected individu-
als presenting with AP, defined as febrile UTI, at primary
care or emergency department.
Methods/Design
A randomized placebo-controlled double-blind multi-
center trial is conducted with the aim to determine non-
inferiority of the primary outcome measure between short
treatment and standard treatment of febrile UTI. Consec-
utive patients will be randomized in a 1:1 ratio stratified
per center and sex, to receive either a 7-day or 14-day reg-
imen of antimicrobial treatment. Those enrolled in the 7-
day regimen will be provided with placebo tablets to
match antimicrobial tablets to complete a 14-day course.
Patients
Inclusion criteria
A subject is eligible for inclusion if all of the following cri-
teria apply: 1) Competent patient aged 18 years or above,
2) One or more solicited symptoms suggestive of urinary
tract infection (UTI) (i.e. dysuria, frequency, urgency,
perineal pain, suprapubic pain, costovertebral tenderness
or flank pain), 3) Fever defined as a measured tempera-
ture ≥ 38.2°C (ear, rectal) or ≥ 38.0°C (axillary) and/or a
history of feeling feverish with shivering or rigors includ-
ing the past 24 hours, 4) Positive urine nitrate test and/or
leukocyturia as depicted by leukocyte esterase test or the
presence of more than 5 leukocyte per high- power field
in a centrifuged sediment.
Exclusion criteria
A subject is not eligible for inclusion in this trial if any the
following criteria apply: 1) Known allergy to fluoroqui-
nolones, 2) Pregnancy or lactation, 3) Polycystic kidneyPage 2 of 9
(page number not for citation purposes)
BMC Infectious Diseases 2009, 9:131 http://www.biomedcentral.com/1471-2334/9/131disease, 4) Permanent renal replacement therapy, 5) His-
tory of kidney transplantation, 6) Residence outside coun-
try of enrollment, 7) Inability to speak or read Dutch and
8) Absence of written informed consent.
In addition to these exclusion criteria patients with the
following conditions, indicating longer or other antimi-
crobial treatment, will not be randomized: 1) Isolation of
ciprofloxacin-resistant causal uropathogen, 2) Presence of
renal abscess, 3) Presence of underlying chronic bacterial
prostatitis and 4) Presence of metastatic infectious foci.
A subject can be included in this study only once.
Setting
Patients eligible for this trial will be recruited at primary
health care centers or at emergency department (ED) of
hospitals in the Leiden region. The primary care region
and participating hospitals serve one single area (North-
West of South Holland) of the Netherlands (Figure 1).
Patients considered ill enough by their primary care phy-
sician to require hospitalization will be enrolled at the
emergency department of affiliating regional hospitals to
which they refer.
Treatment
Subjects will be randomized to receive either short antimi-
crobial treatment for 7 days followed by placebo for 7
days, or standard antimicrobial treatment for 14 days. The
decision whether to treat as outpatient or inpatient will be
made by the attending physician based on clinical judg-
ment. Outpatients will be treated non-blinded with oral
ciprofloxacin (500 mg b.i.d.) for 7 days followed by the
blinded study medication (oral ciprofloxacin 500 mg or
placebo b.i.d.) for 7 days. Inpatients will be empirically
treated according to local guidelines on antimicrobial
treatment (β-lactam ± aminoglycoside intravenously).
After empirical intravenous treatment, patients will be
switched as soon as possible to oral ciprofloxacin. Patients
will then receive non-blinded oral ciprofloxacin (500 mg
b.i.d.) up to the 7th day followed by the blinded study
medication (oral ciprofloxacin 500 mg or placebo b.i.d.)
for additional 7 days. Inpatients that are empirically
treated with oral antimicrobials will be treated as the out-
patients. The placebo is indistinguishable from the cipro-
floxacin containing formula, by sight and taste. Blinded
treatment (ciprofloxacin 500 mg or placebo) is manufac-
tured according to Good Manufacturing Principles princi-
ples by ACE Pharmaceuticals BV, Zeewolde, The
Geographic distribution of participating sitesFigure 1
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blinded.
Patients with an indication of longer or other antimicro-
bial treatment as assessed by the additional exclusion cri-
teria will be treated according to best clinical practice as
judged by the attending physician. Though not rand-
omized, these patients will remain in the study to assess
the outcome.
Data collection and management
Demographic, clinical and microbiological data will be
collected by qualified research nurses or the clinical inves-
tigator (CvN) who will visit all patients at home directly
after they have been notified by the primary care physi-
cians. Data from patients included at the ED will be col-
lected from the medical record completed with an
interview by telephone or at the bedside using a standard-
ized questionnaire. Blood and urine cultures will be taken
before commencement of antimicrobial therapy and are
analyzed by standard microbiological methods at local
certified laboratories. All patients will be contacted by per-
son at day of enrolment, 3–4 days and 28–32 days there-
after and are contacted by phone at 13–15 days and 84–
92 days after enrolment to assess outcome. Urine cultures
will be performed 28–32 days after enrolment to assess
microbiological outcome. In case of (re)admission during
the study period, related data will be taken from the med-
ical record. A detailed flowchart of data registration is out-
lined in Table 1.
Data of clinical and microbiological data are collected in
standardized questionnaires, case record files (CRFs), sub-
jects' diaries and laboratory records. The data will be
entered into a SPSS database using SPSS Data Entry
Builder 4.0. To ensure validity of entrance the data will be
inputted twice. All data sets will be initiated with an audit
trail. The subjects' diaries are considered supportive for
the investigators when filling in the CRFs, i.e. all relevant
information will be translated and transferred to the CRFs
by the research nurses or the clinical investigator. The data
sets will be checked for consistency and plausibility. All
ambiguous or implausible data items will be resolved by
data queries to the investigators in the field.
Randomization
A computer-generated randomization list of permuted
blocks of 4 made by an appointed pharmacist will be used
for treatment allocation. This list contains the numbers 1
to 500 and consists of 125 blocks of 4. The list of rand-
omization numbers and corresponding treatment (pla-
cebo or ciprofloxacin) will be saved in an independent
database with restricted access by the pharmacist. Stratifi-
cation will be done per center site (7 hospitals; all primary
health care centers are considered as one center) and sex.
Each collaborating center will be allocated eight consecu-
tive treatment packages consisting of 2 (one for males and
one for females) consecutive blocks of 4, each time when
needed. Randomization, and thus allocation to study
treatment, will be done once the results of the urine cul-
ture become available at the 3rd or 4th day after inclusion.
Endpoints
Primary endpoint
The primary outcome measure is clinical cure rate,
defined as being alive with resolution of UTI symptoms
and fever, among evaluable patients through the 10- to
18-day post-treatment visit.
Secondary endpoints
The secondary outcome measures are bacteriologic cure
through the 10- to 18-day post-treatment visit, clinical
Table 1: Flowchart of assessments in patients with acute pyelonephritis at time points during follow-up.
Evaluation DAYS AFTER ENROLMENT
0 3–4 13–15 24–32 84–92
Notification to study center X
Entry criteria X
Written Informed Consent X* X*
Demography X
Clinical data X X X X X
(Serious) Adverse events X X X X X
Mortality X X X X
Blood culture X
Urine culture X X
Randomization and allocation to study treatment X
End of treatment assessment X
Contact – in person X X X
Contact – by phone X X
Ad *: After notification at emergency department written informed will be obtained as soon as possible with a maximum till the 4th day.Page 4 of 9
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cause mortality and adverse event rate determined 10- to
18 days and 70- to 84 days post-treatment, rate of UTI
relapse and rate of adverse events during 90 days of fol-
low-up. In addition, the outcome measures will be strati-
fied according to final diagnosis as classified by the
Infectious Diseases Society of America and the European
Society of Clinical Microbiology and Infectious Diseases
[19,20]. This includes analysis of specific subgroups, i.e.,
men, patients with acute complicated pyelonephritis,
patients with any co-morbidity and patients with bactere-
mic UTI.
Definitions
The following definitions will be used. Clinical cure is
defined as being alive with the absence of fever (tempera-
ture < 38.0°C) and the resolution of UTI symptoms
(either absence of symptoms or at least 2 points improve-
ment on a 0 through 5 points severity score) through the
post-treatment visit whereas no additional antimicrobial
therapy for a relapse of UTI is described. Clinical treatment
failure is the opposite of clinical cure and defined as dete-
rioration, persistent fever and/or symptoms of UTI (less
than 2 points improvement on a 0 through 5 points sever-
ity score) or relapse of UTI with the same uropathogen for
which additional antimicrobial treatment is prescribed.
Clinical recurrence is defined as any clinical UTI after clin-
ical recovery and the end of treatment period including
uncomplicated UTI, complicated UTI and acute pyelone-
phritis as defined previously [19]. Based on microbiologi-
cal typing of isolated uropathogen distinction will be
made between clinical relapse, being the same uropatho-
gen or clinical reinfection with a different uropathogen.
Pre-treatment significant growth of uropathogens is defined as
≥ 104 colony forming units/mL in women (midstream
urine) or ≥ 103 colony-forming units/mL in men (mid-
stream urine) or ≥ 103 colony-forming units/mL (catheter
urine) or ≥ 102 colony-forming units/mL of midstream
urine collected during antibiotic treatment of UTI at study
entry [19]. Bacteriologic cure or eradication is defined as
the elimination of the study entry uropathogen or as path-
ogen growth of less than 104 colony forming units/mL in
women or less than 103 colony-forming units/mL in men,
of a midstream urine sample collected combined with the
disappearance of leucocyturia [19]. Bacteriologic failure
through the 10- to 18-day post-treatment visit is defined
as the absence of bacteriologic cure and classified as per-
sistence of the original pathogen or superinfection with a
new pathogen on the basis of species determination and
antibiogram or an alternative method, such as Amplified
Fragment Length Polymorphism or sequence-based PCR
using repetitive extragenic palindromic primers. Cipro-
floxacin resistance of uropathogens is defined by a MIC > 4
mg/L and includes all Enterococcus spp. Acute complicated
pyelonephritis is defined as febrile urinary tract infection in
a person with one or more of the following baseline char-
acteristics: male sex, postmenopausal (female aged ≥ 50
years), underlying urinary tract disorder (e.g. nephrolithi-
asis, urologic malignancy, vesicoureteral reflux, urethral
stricture), diabetes mellitus, immunocompromised, renal
insufficiency or progressive UTI despite antimicrobial UTI
treatment. Co-morbidity is defined as the presence of any
urinary tract disorder, heart failure, cerebrovascular dis-
ease, renal insufficiency, diabetes mellitus, malignancy or
chronic obstructive pulmonary disease for which the
patient is prescribed medication and/or consults a hospi-
tal-based medical specialist.
Ethics
This study is conducted in accordance with the principles
of the Declaration of Helsinki and 'good clinical practice'
guidelines. The independent medical ethics committees
of the participating centers have approved the study pro-
tocol. Written informed consent is obtained prior to ran-
domization; consent by proxy will be obtained for
patients who are temporally unable to provide consent.
Statistical analysis
Sample size
From previous studies the clinical cure rate is estimated to
be approximately 90% [9,10,21]. This study will have
power of 90% to show that the clinical cure rate for Short
treatment (7 days followed by placebo for 7 days) is at
least as high as the cure rate for Standard treatment (14
days). Assuming that the event rates for the Standard treat-
ment and Short treatment populations are 90% and
89.5%, respectively, that a difference of 10,0 points or less
is unimportant, and that alpha (1 tailed) is set at 0.05, the
sample size in the two groups will be 200 each. Formally,
the null hypothesis is that the clinical cure rate for Short
treatment is 10,0 percentage points lower than the cure
rate for Standard treatment, and the study has power of
90% to reject this null. Equivalently, the likelihood is 90%
that the 95,0% confidence interval (CI) for the difference
in clinical cure rates will exclude a 10,0 point difference in
favor of Standard treatment. We adopted 10% as the mar-
gin of non-inferiority as suggested previously [22]. In
order to evaluate 200 patients in both treatment arms and
considering subjects who will discontinue the study for
various reasons, we estimate that 480 patients are needed
to be randomized and 580 patients must be screened for
randomization. According to CONSORT the flow of
expected participants are outlined in Figure 2[23].
Intention to treat, per-protocol and subgroup analysis
The primary endpoint will be analyzed on the Intent-To-
Treat population, including all randomized patients who
received at least one dose of the study drug, and on the
Per-Protocol population, including all randomized
patients who had been given the study drug for a mini-Page 5 of 9
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Recruitment of consecutive patients with acute pyelonephritisFigure 2
Recruitment of consecutive patients with acute pyelonephritis.
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had been taken at least 80% of the study drug (in case of
clinical cure). The primary significance test will be carried
out on the equivalence in cure rates or clinical failure rates
in the two treatment arms.
Descriptive statistics will be used to describe the baseline
characteristics of the participants in each arm. Binomial or
categorical outcome measures will be analyzed using Chi-
square tests (Pearson's or Fisher's). Risk difference with
95% CI will be used to compare the differences of categor-
ical outcomes. The primary outcome variable is clinical
cure rate assessed 10- to 18 days post-treatment. As we are
only interested in non-inferiority and not in equivalence,
the sample size calculation is based on a one-tailed alpha
of 0.05. This implies that the 90% CI of a two-tailed Chi-
square test should not cross the predefined risk difference
of 10% lower clinical cure rate [24].
The primary outcome will additionally been tested in the
subgroups of males, females, patients with acute compli-
cated pyelonephritis, patients with any co-morbidity,
patients aged ≥ 50 years, patients with bacteremic UTI and
patients with stepdown treatment (antimicrobials intrave-
nously followed by oral ciprofloxacin during the first 7
days). Subgroup analysis and all secondary outcome
measures will be analyzed using Chi-square tests.
In case of significant differences in baseline characteris-
tics, which may have happen by chance as we only stratify
randomization by sex and center, the primary outcome
will additionally be tested using a multivariable binary
logistic regression model to adjust for the following
potential confounders: age, acute complicated pyelone-
phritis, underlying co-morbidity and the use of stepdown
treatment.
Safety
Adverse events will be monitored by passive self-reporting
and active surveillance at each follow-up visit or tele-
phone call; the rates of adverse events within the two treat-
ment arms will be compared. Safety data will be subject to
clinical review and summarized by appropriate descrip-
tive statistics. In case of treatment failure the attending
physician will prescribe additional antimicrobial treat-
ment, as appropriate. Such 'rescue medication' will be
offered by the study team.
An independent Data and Safety Monitoring Board
(DSMB) will monitor safety on an ongoing basis through-
out the trial. Safety reports summarizing Serious Adverse
Events (SAE) will be submitted to the Chair of the DSMB
after each SAE. In addition, the DSMB will review the
results of the interim analyses scheduled to occur after
approximately 25, 50 and 75 percent of the patients have
completed until the 10- to 18-days post-treatment visit.
The objective of the interim analyses is to consider stop-
ping for safety reasons only. The breaking of the blind and
the analysis of the data will be performed by a pharmacist
and the members of DSMB. The following stopping rules
are predefined during each interim analysis: 1). Regarding
the primary outcome measure, Short treatment is definite
inferior to Standard treatment with statistical significance
of ≥ 95% certainty and 2). The clinical cure rate in the
Standard arm is <75%. Besides these stopping rules, the
judgment of the DSMB will be based upon a general
review of adverse events including 30-day mortality. The
initial communication to the study team will consist only
of the outcome of the decision: either 1) there is sufficient
evidence to consider stopping the trial or 2) there is insuf-
ficient evidence to consider stopping the trial.
Registration
This study is registered at clinicaltrials.gov
[NCT00809913] and trialregister.nl [NTR01583] with the
acronym FUTIRST-trial used.
Discussion
UTIs in adults are classified into acute uncomplicated UTI,
acute uncomplicated pyelonephritis, complicated UTI
(CUTI), acute complicated pyelonephritis and in addi-
tion, for men there are several categories of prostatitis
[11,12,19,25]. The term 'uncomplicated' is usually
restricted to non-pregnant women without underlying
functional or anatomical abnormalities of the urinary
tract but it remains controversial whether older, postmen-
opausal, women and women with other underlying co-
morbidities, like diabetes mellitus, also belong to this
group [20]. Pyelonephritis is defined as a serious infection
involving the pelvis, calices and kidney parenchyma
which is classically characterized by fever, flank pain or
costovertebral angle tenderness and signs and symptoms
of UTI. While treatment recommendations of acute
uncomplicated UTI and acute uncomplicated pyelone-
phritis are quite straightforward with short oral antimicro-
bial courses on an outpatient basis, there is a lack of
conformity on therapeutic approaches for CUTI and acute
complicated pyelonephritis; likely because these condi-
tions reflect a broad spectrum of clinical syndromes.
Therefore from a pragmatic viewpoint it is reasonable to
classify these patients according to their clinical presenta-
tion in which fever reflects whether there is a parenchymal
inflammation or not. Whether this involves the kidney,
bladder, prostate, lymph nodes of the pelvis, blood circu-
lation or a combination of those cannot be assessed on
clinical grounds. In the literature, fever in UTI is mostly
attributed to AP [1,2]. In this study we use febrile UTI as
the clinical syndrome of interest because this is how
patients present and fever mainly determines the appro-
priate treatment. According to existing classifications thisPage 7 of 9
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been suggested, the urosepsis syndrome [26]. However,
for reasons of simplicity and clinical pragmatics we con-
sider FUTI as a clinical appearance of AP [1,2].
This study is different from previous studies that address
treatment duration of AP. One study included only
women with uncomplicated AP and a median age of 25
years [9] while another recent study included predomi-
nantly women aged ≤ 45 years of which a small subgroup
suffered complicated AP [10]. Based on the results of these
studies, it can be concluded that uncomplicated AP can be
effectively treated in young women with a 5–7 day course
of fluoroquinolones. However, the treatment duration
was not the only study objective because the comparators
in these studies were other antimicrobial agents. Therefore
it remains unclear whether longer treatment of AP with
fluoroquinolones might be even better. Other clinical tri-
als on AP did not examine treatment duration but most of
them compared newer or extended release fluoroquinolo-
nes to conventional ones. In all these studies, treatment
duration was variable being 5 to 14 days [27-31]. From
these trials it seems evident that AP in many cases can be
treated shorter than 14 days. Nevertheless caution is war-
ranted to generalize this to common practice because the
study populations were highly selected being predomi-
nantly women who were relatively young and healthy.
Furthermore, both patients with AP and CUTI were
included in which fever was not a prerequisite of inclu-
sion and the majority of cases had CUTI. In other words
one might only conclude from these studies that cystitis in
a complicated person can effectively be treated with fluo-
roquinolones less than 14 days. Based on the evidence in
the literature we therefore conclude that the duration of
antimicrobial treatment in patients with uncomplicated
AP could be as short as 5–7 days whereas in patients with
complicated AP it is unclear and should be at least 14
days.
In contrast to previous studies, the current study includes
consecutive patients with febrile UTI, being AP, reflecting
the daily clinical practice of primary care and emergency
departments. This includes male participants who by def-
inition are classified as complicated. This might be con-
troversial but from a pathophysiological point of view
there is no reason to believe that AP in men behaves dif-
ferent from AP in women. Indeed, previous studies that
included a sufficient number of men, showed that treat-
ment of febrile UTI with fluoroquinolones for 7–14 days
had comparable clinical cure rates of about 90% [28,30-
32]. Moreover, we recently evaluated the guideline of the
Dutch College of General Practitioners that recommends
antimicrobial treatment of febrile UTI for 10 days irre-
spective of sex [33]. In this observational study with simi-
lar inclusion criteria, male sex was not a risk factor for
clinical failure [21]. As in previous studies, the mortality
rate in men was higher but this reflects underlying co-
morbidity rather than attributable risk of UTI [5,21].
Based on the results of these studies we conclude there is
sufficient evidence to include men in such a trial as this.
Furthermore, it should be emphasized that although men
with suspected chronic bacterial prostatitis are excluded
from this trial it might be that men with febrile UTI have
indeed acute prostatitis. However, as recommended treat-
ment durations of acute prostatitis are primarily based on
expert opinion (being 14 days) and the distinction of
febrile UTI in men between pyelonephritis or prostatitis
can often not be made clinically, a trial evaluating the
optimal treatment duration is even more relevant in this
population [34].
In contrast to all previous studies, the study objective of
this trial only involves treatment duration. Combined
with the inclusion of patients reflecting routine daily prac-
tice these aspects are thus unique that it is named with the
acronym FUTIRST (Febrile UTI Randomized Short Treat-
ment)-trial to put emphasis on being the first clinical trial
on febrile UTI or AP with such a pragmatic design. Meet-
ing the criteria for a practical clinical trial, the results of
this study are thus generalizable to other settings and
should influence policy makers of treatment guidelines
on AP [35].
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